横琴企业全国首创穿刺手术机器人！临床手术突破5000例

Core Insights - The second China Respiratory Health Conference was held in Guangzhou, where Guangdong Zhenjiankang Medical Technology Co., Ltd. announced that its "domestically pioneering" puncture surgery robot has completed over 5,000 clinical surgeries [1][2] - The robot is currently utilized in nearly 100 medical institutions across more than 20 provinces in China, covering various clinical departments such as thoracic surgery, respiratory medicine, interventional medicine, and oncology [1] - Zhenjiankang is recognized as a national high-tech enterprise and a "specialized and innovative" small giant enterprise, focusing on the research and industrialization of soft tissue puncture diagnosis and organ repair intelligent robots [1] Product Development and Recognition - The puncture surgery robot was approved for market launch in May 2022, marking it as the first percutaneous puncture surgery robot approved in China [1] - In June 2023, an upgraded version of the robot received Class III innovative medical device certification from the National Medical Products Administration and was recognized as a "domestically pioneering" product [1] - The company has also contributed to the establishment of the first expert consensus on the clinical application of puncture surgery robots in China, creating a comprehensive operational service system that integrates research, market, academic collaboration, and clinical efficiency [1] Market Impact - The founder of the company, Zhang Hao, stated that the robot's safety, precision, and efficiency are becoming significant drivers for improving regional diagnostic and treatment levels [2] - The milestone of 5,000 clinical surgeries not only validates the technical feasibility and effective exploration of the business model but also establishes a solid market trust system for the robot [2] - This development signifies the arrival of a new era of percutaneous puncture surgery robots that are widely recognized in clinical settings and developed independently in China [2]